Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2008
02/21/2008US20080045498 Polycyclic viral inhibitors
02/21/2008US20080045497 Substituted aniline derivatives
02/21/2008US20080045496 Inhibit tyrosine kinase activity of Trk receptors; antiproliferative agents, anticancer agents; cancer, psoriasis or rheumatoid arthritis; N4-pyrazol-5-yl-pyrrolo[2,1-f] [1,2,4]triazine-2,4-diamines
02/21/2008US20080045495 Treatment of Patients with Cystic Disease by Alteration of Fibrocystin Proteolysis
02/21/2008US20080045494 Pyridine Analogues VI
02/21/2008US20080045493 such as Parkinson's disease, schizophrenia, cognitive disorders, depression, anxiety, drug addiction, eating disorders and urogenital disorders; 4-(2,2-Difluoro-cyclopropyl)-N-[4-(1-propyl-piperidin-3-yl)-phenyl]-benzenesulfonamide
02/21/2008US20080045492 Mitotic Kinesin Inhibitors
02/21/2008US20080045490 Pharmaceutical Compositions
02/21/2008US20080045489 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
02/21/2008US20080045488 Combination of a phytoestrogen compound such as an isoflavone and a progestin such as norgestimate, levonorgestrel, norgestrel, norethindrone, desogestrel, gestodene, dienogest and/or drospirenone; hormone replacement therapy and contraceptives
02/21/2008US20080045487 Pharmaceutical formula for treating skin disease
02/21/2008US20080045486 Ocular administration of testosterone
02/21/2008US20080045485 Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture
02/21/2008US20080045484 Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus
02/21/2008US20080045483 such as 4-{2-[2-(4-chlorobenzenesulfonylamino)phenyl]ethyl}benzoic acid; hyperglycemic agents
02/21/2008US20080045482 Compositions and methods for the treatment of viral infections
02/21/2008US20080045481 Novel co-crystal
02/21/2008US20080045480 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
02/21/2008US20080045479 Compositions and methods for regulating mammalian keratinous tissue
02/21/2008US20080045478 For skin/hair light protection; cosmetics
02/21/2008US20080045477 Series Of New 4,6-Diamino-1,2-Dihydro-1-Aryl-1,3,5-Triazines, Substituted By An Adamantyl Moiety In The Position 2 Of Triazine-Their Corresponding Salts, Isomers,Steroisomers, Enantiomers, Free Bases And The Complexes Of All The Above With Natural Macromolecules And Their Synthetic Derivatives.
02/21/2008US20080045476 Methods and compositions using sulodexide for the treatment of diabetic nephropathy
02/21/2008US20080045475 Elemental cellular therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and homeostatic processes
02/21/2008US20080045474 Method for treatment of invasive cells
02/21/2008US20080045473 Compositions and methods for oligonucleotide formulations
02/21/2008US20080045472 Targets for human micro rnas in avian influenza virus (h5n1) genome
02/21/2008US20080045470 Ceramides and Apoptosis-Signaling Ligand
02/21/2008US20080045469 Compositions and Methods for Inhibiting Angiogenesis
02/21/2008US20080045468 Antimicrobial 2-deoxystreptamine compounds
02/21/2008US20080045467 Composition Containing Ginsenoside F1 Or Compound K For Skin External Application
02/21/2008US20080045466 Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
02/21/2008US20080045465 Phosphole Derivatives Complexed with Metals, and Pharmaceutical Uses Thereof
02/21/2008US20080045464 Natural Sweetener
02/21/2008US20080045463 Methods For Lowering Hif-1 Mediated Gene Expression
02/21/2008US20080045459 Orally administered peptides synergize statin activity
02/21/2008US20080045457 Ancestral Hepatitis C virus envelope protein sequence
02/21/2008US20080045454 Polynucleotide encoding a TRIM-cyp polypeptide, compositions thereof, and methods of using same
02/21/2008US20080045451 Novel thymidylate synthase mutants
02/21/2008US20080045449 Novel Lipid Mixtures For Synthetic Surfactants
02/21/2008US20080045448 Reversing autonomic nervous system dysfunction by potentiating methylation
02/21/2008US20080045445 Modulating Notch1 Signaling Pathway for Treating Neuroendocrine Tumors
02/21/2008US20080044881 Advanced Indolinone Based Protein Kinase Inhibitors
02/21/2008US20080044500 extract of a plant of the family Liliaceae; Aloe vera; can be safely ingested without causing acute hypoglycemia and has a long-term blood glucose level control action to decrease the hemoglobin Alc level
02/21/2008US20080044499 Sleep Improvement Composition
02/21/2008US20080044497 Methods and Pharmaceutical Compositions Useful for Treating Psoriasis
02/21/2008US20080044493 Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer
02/21/2008US20080044491 Metal-containing formulations and methods of use
02/21/2008US20080044490 Sterile low bicarbonate dialysis concentrate solutions
02/21/2008US20080044487 Anti-inflammatory properties of marine lipid compositions
02/21/2008US20080044486 Controlled Food Effect Composition
02/21/2008US20080044485 increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures; microparticles; drugs such as risperidone
02/21/2008US20080044482 Orally administrable opioid formulations having extended duration of effect
02/21/2008US20080044481 Microparticles for Oral Delivery
02/21/2008US20080044478 Preparation of injectable suspensions having improved injectability
02/21/2008US20080044476 Mixture of corticosteroid and sodium hyaluronate in aqueous carrier
02/21/2008US20080044475 Forming microemulsions of diacetates and dipropionates of lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, or astaxanthin, or a monoacetate or monopropionate of cryptoxanthin; nutrition supplements; pigmenting skin of broilers and egg yolks.
02/21/2008US20080044472 Photoresponsive Hydrogels
02/21/2008US20080044471 Neurotherapeutic compositions
02/21/2008US20080044468 Processes For The Preparation Of Oral Dosage Formulations Of Modafinil
02/21/2008US20080044467 Formulation and process for drug loaded cores
02/21/2008US20080044466 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
02/21/2008US20080044465 Therapy for cellular accumulation in chronic inflammatory diseases
02/21/2008US20080044464 Liposome loading with metal ions
02/21/2008US20080044462 Stabilized transdermal bupropion preparations
02/21/2008US20080044461 Transdermal methods and systems for treating Alzheimer's disease
02/21/2008US20080044457 Antitumor agents; time-release agents; pulverization
02/21/2008US20080044456 Cellulose membrane drying process
02/21/2008US20080044455 Tonsillitus Treatment
02/21/2008US20080044453 Therapeutic Agent for Treatment of Autoimmune Diseases
02/21/2008US20080044452 Drug delivery system for treatment of transitional cell carcinoma
02/21/2008US20080044439 Compositions and Methods for Preventing and Treating Skin and Hair Conditions
02/21/2008US20080044432 Mammalian receptor proteins; related reagents and methods
02/21/2008US20080044428 Glycosylphosphatidylinositol Glycan Signalling Via Integrins Functioning as Glycan Specific Receptors
02/21/2008US20080044422 CNGH0010 Specific Polynucleotides, Polypeptides, Antibodies, Compositions, Methods and Uses
02/21/2008US20080044418 Tumor Antigens and Uses Thereof
02/21/2008US20080044416 Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
02/21/2008US20080044414 IL-1beta binding antibodies and fragments thereof
02/21/2008US20080044411 Human glp-1 mimetibodies, compositions, methods and uses
02/21/2008US20080044409 Inflammatory mediator antagonists
02/21/2008US20080044406 Neuroactive fragments of APP
02/21/2008US20080044403 Immune Markers Used for Diagnosis and Therapy in Connection With Transplant Reactions
02/21/2008US20080044401 Drug therapy for celiac sprue
02/21/2008US20080044394 Methods for genetic modification of hematopietic progenitor cells and uses of the modified cells
02/21/2008US20080044393 Retinal dystrophin transgene and methods of use thereof
02/21/2008US20080044390 Methods and compositions for the treatment of neurodegenerative disorders
02/21/2008US20080044389 Mortierella schmuckeri microorganisms are cultured in fermentation medium; a polyunsaturated fatty acid for use in food products, nutraceuticals e.g. infant formulas
02/21/2008US20080044388 Method for Production of Arachidonic Acid
02/21/2008US20080044385 Novel Modified Galectin 8 Proteins and Use Thereof
02/21/2008US20080044380 Hepatitis C Virus Inhibitors
02/21/2008US20080044379 (1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) -N,N-dimethyl-2-oxo-1-phenylethanamine; inhibit the function of the non-structural proteins (NS5A)
02/21/2008US20080044378 Methods and Compositions for Protein Production Using Adenoviral Vectors
02/21/2008US20080044374 Polymer cement for percutaneous vertebroplasty and methods of using and making same
02/21/2008US20080044373 Cosmetic composition for the lips, combining a phosphate surfactant and a silicone polymer
02/21/2008US20080044371 Taste-Masked Composition of Cationic Exchange Resin
02/21/2008US20080044364 Flavonoid Complexes
02/21/2008US20080044361 The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1 7-((hydroxydi-2-thienylacetyl)oxy)-9, 9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane-bromide, with a simple monoclinic cell, and one or more adjuvants
02/21/2008US20080044355 including cystic fibrosis transmembrane conductance regulator ("CFTR"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease
02/21/2008US20080044354 Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation
02/21/2008US20080044353 Combination Therapy for Weight Management
02/21/2008US20080042818 Trailer tire alert system